Personalizing the Selection of Systemic Therapies for Moderate-to-Severe Atopic Dermatitis
Podcast 5: Reviewing Systemic Therapies for Patients with Moderate-to-Severe Atopic Dermatitis
Post-Test/Evaluation
Exit Survey
Questions marked with a
*
are required
20%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Treatment of moderate-to-severe AD:
Use of oral prednisone should be discouraged
Dupilumab is efficacious in those patients refractory to topicals
Systemic immunosuppressant use in pediatrics should be limited
JAK inhibitors are efficacious but have limited safety data
B and D
An 8 y/o girl with her Mom are in for a follow-up visit. Daughter can’t sleep and is having difficulty in school due to itching. She’s maintained on moisturizer and low potency TCS. Options?
Add tralokinumab
Add dupilumab
Add Abrocitinib
Switch to TCI
All of the above
B and D
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close